Express Scripts, the pharmacy benefits unit of Cigna Group, announced its decision to add three biosimilar versions of AbbVie’s widely used arthritis treatment, Humira, to its list of preferred drugs. The biosimilars include Hyrimoz, an unbranded version of Humira developed by Novartis’ Sandoz generics division, and Cyltezo from German drugmaker Boehringer Ingelheim. 

Sandoz, a Swiss drug manufacturer, revealed that its unbranded biosimilar, chemically known as adalimumab-adaz, will be priced at a remarkable 81% discount compared to Humira’s current list price of $6,922 per month. Additionally, Hyrimoz will be offered at a 5% discount. Boehringer Ingelheim stated that Cyltezo will be launched at a price 5%-7% below Humira’s list price.